Trial Profile
Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- 03 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
- 08 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2025.